8-K: Shattuck Labs Announces Q3 2024 Financial Results and Strategic Shift to SL-325 Development

Shattuck Labs reported its Q3 2024 financial results, highlighted by a strategic focus on SL-325 development and a cash runway extending into 2027.

Summary

• Shattuck Labs announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company is strategically shifting its focus to the development of SL-325, a first-in-class DR3 blocking antibody.
• Shattuck has completed restructuring plans to support the development of SL-325.
• The company's cash balance was approximately $90 million as of September 30, 2024.
• This cash balance is expected to fund operations into 2027.
• Research and development expenses were $16.3 million for the quarter, compared to $24.2 million in the same quarter of 2023.
• General and administrative expenses were $4.6 million for the quarter, compared to $5.1 million in the same quarter of 2023.
• The net loss for the quarter was $16.7 million, or $0.33 per share, compared to a net loss of $27.5 million, or $0.65 per share, in the same quarter of 2023.
• An IND filing for SL-325 is expected in the third quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with a strategic focus on a promising drug candidate and a strong cash position, but there are still risks associated with clinical development and the company is still loss making.

Positives

• The company has a strong cash position of $90 million, which is expected to fund operations into 2027.
• The net loss has significantly decreased year-over-year, indicating improved financial performance.
• The strategic shift to focus on SL-325 is a positive move, as it is a first-in-class antibody with promising potential.
• The company has completed its restructuring plans, which should lead to more efficient operations.
• The company is actively progressing SL-325 through preclinical studies with an IND filing expected in Q3 2025.

Negatives

• The company experienced a net loss of $16.7 million for the quarter.
• Cash reserves have decreased from $101.1 million in September 2023 to $90.1 million in September 2024.
• The company has discontinued the development of SL-172154, which may have some negative implications.

Risks

• The company's future success is heavily reliant on the successful development and commercialization of SL-325.
• Clinical trials may not yield the expected results, and regulatory approvals may not be granted.
• The company's cash runway is based on current operational plans and excludes potential additional costs or business development activities.
• There are risks associated with the company's restructuring and reduction in force.
• The company is subject to various risks and uncertainties, including those related to global macroeconomic conditions.

Future Outlook

Shattuck believes its current cash and investments will be sufficient to fund operations into 2027, beyond the results of the Phase 1 clinical trial of SL-325. This guidance excludes any additional capital, business development proceeds, or additional development costs.

Management Comments

• Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck, stated that the company is underway with IND-enabling studies for SL-325.
• The CEO also mentioned that the company has substantively completed its restructuring plans to focus on the development of SL-325.

Industry Context

The strategic shift to focus on SL-325 aligns with the growing interest in targeting the TL1A/DR3 pathway for the treatment of autoimmune and inflammatory diseases. This move positions Shattuck to potentially compete with other companies developing therapies in this space.

Comparison to Industry Standards

• Shattuck's focus on a first-in-class DR3 antagonist antibody is a novel approach compared to companies targeting the TL1A ligand, such as Prometheus Biosciences (now part of Merck) with PRA023.
• The reported cash runway into 2027 is a positive sign, as many biotech companies face funding challenges, and this provides a longer period for clinical development.
• The reduction in R&D expenses suggests a more focused approach, which is a common strategy for biotech companies in the clinical stage.
• The improvement in net loss compared to the previous year is a positive trend, but the company still needs to achieve profitability.
• Companies like Roivant Sciences and others are also exploring TNF superfamily targets, making this a competitive landscape.

Stakeholder Impact

• Shareholders may view the strategic shift and improved financial performance positively.
• Employees may be impacted by the restructuring and reduction in force.
• Customers and suppliers may be affected by the company's focus on SL-325.
• Creditors may be reassured by the company's cash runway into 2027.

Next Steps

• Shattuck will continue IND-enabling studies for SL-325.
• The company plans to file an IND for SL-325 in Q3 2025.
• Shattuck will attend investor conferences in December 2024.
• The company will continue to develop SL-325 through clinical trials.

Key Dates

Keywords

SL-325, DR3 antagonist, TL1A, biotechnology, clinical trials, IND filing, financial results, restructuring, cash runway, research and development